西格列汀治疗2型糖尿病患者临床观察

Clinical observation of Sitagliptin in treatment of patients with type 2 diabetes

目的观察西格列汀对2型糖尿病患者的临床疗效及安全性。方法将64例正在口服降糖药二甲双胍片的2型糖尿病患者随机分为两组,对照组继续口服二甲双胍片,治疗组在原来治疗方案基础上加用西格列汀片口服。临床治疗12周后,测定两组患者空腹血糖(FBG)、餐后2h血糖(2h PG)、糖化血红蛋白(Hb A1c)、体脂指数(BMI)、血脂、血常规、血压、肝肾功能、不良反应等。结果治疗组在用药12周后,两组患者FBG、2h PG、Hb A1c、BMI均有所下降,但治疗组较对照组下降明显,具有统计学意义(P<0.05)。治疗后两组在血脂、血常规、血压、肝肾功能、不良反应等方面无明显差异(P>0.05),但是治疗组血白细胞(WBC)较对照组有显著下降(P<0.05)。结论使用西格列汀治疗2型糖尿病疗效显著,不增加低血糖风险,安全性较高,临床上可作为一线药物使用。

Objective To observe the clinical efficacy and safety of Sitagliptin for patients with type 2 diabetes. Methods Totally 64 cases of type 2 diabetic patients were randomly divided into oral antidiabetic drug metformin is into two groups, The control group continued metformin tablets, the treatment group based original on the treatment with sita- gliptin tablets clinical treatment after 12 weeks, determination of two groups of patients with impaired fasting glucose （FBG） ,2 hour postprandial blood glucose （ 2hPG）, glycosylated hemoglobin （ HbA1 c ）, body mass index （ BMI ）, blood lipid, routine blood test, blood pressure, the function of liver and kidney, adverse reaction. Results The treatment group in 12 weeks after administration, two groups of patients with FBG, 2hPG, HbAlc, BM! were decreased, but the treat- ment group decreased significantly than the, The statistical significance （ P 〈 0.05 ）. The two groups after treatment on blood lipid blood routine, liver and kidney function, blood pressure, adverse reaction etc. No obvious difference （ P 〉 0.05 ）, but the treatment group of white blood cells （WBC） compared with the control group was significantly decreased （ P 〈 0. 05 ）. Conclusion The use of sitagliptin in treatment of type 2 diabetes meUitus, the curative effect is remarkable, go not increase the risk of hypoglycemia, high security, can be used as the firstline drug.